郑小虎

个人信息Personal Information

特任教授

博士生导师

硕士生导师

电子邮箱：

学历：博士研究生毕业

办公地点：中国科学技术大学西区生医部K616室

学位：博士

毕业院校：中国科学技术大学

学科：生物学

同专业博导同专业硕导

论文成果

当前位置：中文主页 >> 科学研究 >> 论文成果

[1] Sanyou Chen#, Wanhe Li#, Xiaohu Zheng#, Pei Yu, Pengfei Wang, Ziting Sun, Yao Xu, Defeng Jiao, Xiangyu Ye, Mingcheng Cai, Mengze Shen, Mengqi Wang, Qi Zhang, Fei Kong, Ya Wang, Jie He, Haiming Wei, Fazhan Shi*, and Jiangfeng Du*, Immunomagnetic microscopy of tumor tissues using quantum sensors in diamond. PNAS. 2021 Dec 21. In press, (IF=11.205).
[2] Xiaohu Zheng*, Yaqi Wu, Jiacheng Bi, Yingying Huang, Ying Cheng, Yangyang Li, Yuwei Wu, Guoshuai Cao, Zhigang Tian*, The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol. 2022 Feb;19(2):192-209 (IF=11.531).
[3] Defeng Jiao, Xiaohu Zheng*, Xianghui Du, Dong Wang, Ziming Hu, Rui Sun, Zhigang Tian, Binqing Fu*, and Haiming Wei*, Immunogenic senescence sensitizes lung cancer to LUNX-targeting therapy. Cancer Immunol Immunother. 2021 Oct 21. doi: 10.1007/s00262-021-03077-1 (IF=6.968).
[4] Zhigang Nian, Xiaohu Zheng*, Yingchao Dou, Xianghui Du, Li Zhou, Binqing Fu, Rui Sun, Zhigang Tian, Haiming Wei*, Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells, Clinic Cancer Research, 2021, DOI: 10.1158/1078-0432. (IF=12.703).
[5] Jiacheng Bi, Chaoyue Zheng and Xiaohu Zheng*. Increased expression of adenosine A3 receptor in tumor-infiltrating natural killer cells. Cell Mol Immunol. 2021, DOI: 10.1038/s41423-020-00632-1. (IF=11.531).
[6] Xiaohu Zheng, Haiming Wei*. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. 2021, Front Oncol, DOI: 10.3389/fonc.2021.628243. (IF=6.242).
[7] Yonggang Zhou#; Binqing Fu#; Xiaohu Zheng#; Dongsheng Wang; Changcheng Zhao; Yingjie qi; Rui Sun; Zhigang Tian; Xiaoling Xu*; Haiming Wei*. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. National Science Review. 2020, DOI:10.1093/nsr/nwaa041. (IF=17.275).
[8] Xin Zhang, Dong Wang, Zhidong Li, Defeng Jiao, Linlin Jin, Jingjing Cong, Xiaohu Zheng* and Lijun Xu*. Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. Front Immunol, Feb 2020, Volume 11. (IF=7.562).
[9] Xiaohu Zheng, Yeben Qian, Binqing Fu, Defeng Jiao, Yong Jiang, Peng Chen, Yiqing Shen, Huafeng Zhang, Rui Sun, Zhigang Tian* and Haiming Wei *, Mitochondrial fragmentation limits natural killer cell-based tumour immunosurveillance. Nature Immunology, 2019 Dec, 20;1656-1667. (IF=25.6).
[10] Yong Jiang#, Xiaohu Zheng#, Defeng Jiao, Peng Chen, Yechuan Xu, Haiming Wei*, Yeben Qian*. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. EBioMedicine, 2019 Feb;40:422-431. (IF=8.141).
[11] Xiaohu Zheng , Fan X, Fu B, Zheng M, Zhang A, Zhong K, Yan J, Sun R, Tian Z*, Wei H*, EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance. Cancer Research, JAN 15 2017, 77; 482-493. (IF=12.703).
[12] Xiaohu Zheng, Min Cheng, Binqing Fu, Xiaolei Fan, Qing Wang, Xiaoqing Yu, Rui Sun, Zhigang Tian*, Haiming Wei*. Targeting LunX inhibits non-small-cell lung cancer growth and metastasis. Cancer Research, March 15, 2015 75; 1080-90. (IF=12.533).
[13] Xiaohu Zheng, Zhigang Tian, Haiming Wei*. Lung specific X protein as a novel therapeutic target for lung cancer. OncoImmunology, 2015 Aug 17;4(12):e1052931. (IF=8.114).
郑小虎,郑小虎.Targeting LUNX Inhibits Non-Small Cell Lung Cancer Growth and Metastasis.CANCER RESEARCH,2015,75(6):1080-1090.
郑小虎,郑小虎.Lung specific X protein as a novel therapeutic target for lung cancer.ONCOIMMUNOLOGY,2014,4(12):

共17条 1/2

首页上页下页尾页页